Chugai Files For Additional Indication Of Ovarian Cancer For Avastin
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceuticals announced on Oct. 5 that it has filed for an additional indication for anti-cancer drug Avastin (bevacizumab) for ovarian cancer.